Non-invasive cervical cancer prototypes show promise
This article was originally published in Clinica
Prototypes of a non-invasive cervical cancer detection device have shown promising early results in US feasibility studies. The devices, developed by Welch Allyn and SpectRx, produced results that correlated with histology in the identification of high- and low-grade cervical lesions, some of which had been wrongly classified by traditional Pap smears, the US companies said.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.